The Characteristic Factors of Clinical Studies Influencing on the Research Management of the Institutional Review Boards

임상연구 특성요소가 IRB의 임상연구관리에 미치는 영향

  • Chi, Yoon-Hee (Graduate School of Public Health, The Catholic University of Korea) ;
  • Bang, Joon-Seok (Department of Pharmacy, Kangnam St.Mary's Hospital) ;
  • Kim, Yeong-In (Department of Neurology, The Catholic University of Korea) ;
  • Kim, Kyung-Soo (Department of Family Medicine, The Catholic University of Korea) ;
  • La, Hyen-Oh (Department of Phamacology, The Catholic University)
  • 지윤희 (가톨릭대학교 보건대학원) ;
  • 방준석 (강남성모병원 약제팀) ;
  • 김영인 (가톨릭대학교 신경과학교실) ;
  • 김경수 (가톨릭대학교 의과대학 가정의학교실) ;
  • 나현오 (가톨릭대학교 의과대학 약리학교실)
  • Published : 2008.12.30

Abstract

Background: The number of clinical trials which have been performed within Korea is increasing accompanied by the enlargement of the various responsibilities of each Institutional Review Board (IRB) in the way of providing adequate and on-time managerial involvements on the studies. Many confounding factors of each study can influence on the results with which delaying the final reports, or extending the review times associated with research-periods, or adjusting the alterations. Even though these factors were closely related to the results being managed by the IRBs, no in-depth research have been implemented to elucidate the correlations between these factors and the results necessitates IRBs' managements. Methods: Study subjects were selected and analyzed retrospectively in a University hospital's database. About 190 study projects which had been completed during 2005 to 2007 were retrieved and the characterized factors were classified into seven categories. Each category was analyzed and tested statistically by SAS program. Results: It is revealed that a large portion of the factors was subjected to the study profiles. The review-time showed extended tendency in the subjects which used medications (P=0.0174) required approval (P=0.0009) in phases I II III (P<0.0001) initiated by sponsors (P<0.0001) and with duration of 1 to 2 years (P=0.0442). Prior to submitting IRB, correction-times were multiplied specifically on the study subjects that used medications (P<0.0001) required approvals (P<0.0001), underwent phase I II III (P<0.0001) reviewed twice (P=0.0074) initiated by sponsors (P<0.0001) exceeded 2 years of period (P<0.0001) and required modifications before the submission (P=0.0001). Conclusion: The clinical study projects characterize by 'medication-used', 'sponsor-initiated', 'approval-required', 'duration period of 1 to 2 years', and 'under phase I II III' required thorough concerns and investigations from the beginning stage to reduce the time of review by the IRBs. Studies lasted more than 2 years entailed preparation of the sudden alterations to prevent the study duration. A new further study is necessary to analyze the frequency and the causes of the alterations in the study proposals.

Keywords